Company Information

  

Address: 200 - 3650 GILMORE WAY  
City: BURNABY 
State:  
Zip Code: V5G 48W 
Telephone: (604) 484-3300 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy and pain. To date, our pharmaceutical collaborations have generated in aggregate over $160.0 million in non-equity funding with the potential to provide us with future milestone payments, as well as royalties on product sales. Our current pharmaceutical partners include Genentech, a member of the Roche Group, and Merck & Co., Inc., or Merck (through its affiliate, Essex Chemie AG).  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-1.50NAN/E
12/2017-1.72NAN/E
09/2017-1.58NAN/E
06/2017-1.67NAN/E
03/2017-1.68NAN/E
12/2016-1.48NAN/E
09/20160.77NA10.52
06/20163.19NA1.85

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.15Total Liab/Total Assets0.22
Net Inc/Total Assets-0.67Total Liab/Inv Cap0.25
Net Inc/Inv Cap-0.74Total Liab/Comm Equity0.05
Pretax Inc/Net Sales-98.73Interest Coverage RatioNA
Net Inc/Net Sales-98.73Curr Debt/Equity0.02
Cash Flow/Net Sales-92.37LTD/Equity0.17
SG&A/NetSales23.51Total Debt/Equity0.19
Asset Utilization   Liquidity  
Net Receivables Turnover0.97Quick Ratio10.98
Inventory TurnoverNACurrent Ratio10.98
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.01Inv/Curr AssetsNA
Net Sales/PP&E0.29  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.00 0.02 0.26 0.02
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 2.24 1.67 1.74 1.80
Operating Income -7.82 -8.05 -8.64 -7.89
Interest Exp 0.16 NA NA 0.00
Pretax Income -3.76 -8.07 -7.74 -7.38
Other Income 4.22 -0.01 0.90 0.51
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -3.76 -8.07 -7.74 -7.38

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 35.08 43.67 43.77 51.70
Receivables - Total 0.43 0.44 0.13 0.20
Inventories - Total NA NA NA NA
Total Current Assets 36.66 44.82 44.99 52.63
Net Property, Plant & Equipment 1.10 1.07 1.15 1.31
Total Assets 37.76 46.12 46.36 54.23
Liabilities        
Accounts Payable 2.39 3.38 3.06 3.77
Debt in Current Liabilities 1.40 0.70 NA NA
Total Current Liabilities 3.79 4.08 3.06 3.77
Long-Term Debt 5.48 6.10 NA NA
Total Liabilities 9.26 10.19 3.06 3.77
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 21.83 NA NA NA
Common Stock 147.89 173.84 173.84 173.84
Retained Earnings -177.14 -173.39 -165.32 -157.58
Treasury Stock NA NA NA NA
Total Stockholders' Equity 28.50 35.93 43.30 50.45
Total Liabilities and Stockholders' Equity 37.76 46.12 46.36 54.23

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -8.22 -6.84 -8.63 -6.80
Net Cash Provided by Investing Activities 4.98 5.80 -0.09 9.33
Net Cash Provided by Financing Activities 0.12 6.89 0.00 0.00

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201327.3612.03--
12/201428.3713.023.28
12/201515.58-15.751.10
12/20161.80-23.00-1.48
12/20170.31-30.70-1.72
Growth Rates-67.35----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18376,34935.96




Report Date : 7/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.